• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Seer Inc.

    4/13/26 4:37:26 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $SEER alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)


    Seer, Inc.

    (Name of Issuer)


    Class A Common Stock, par value $0.00001 per share

    (Title of Class of Securities)




    81578P106

    (CUSIP Number)
    BRADLEY L. RADOFF
    2727 Kirby Drive, Unit 29L,
    Houston, TX, 77098
    713-482-2196


    MICHAEL TOROK
    68 Mazzeo Drive,
    Randolph, MA, 02368
    617-680-6709


    RYAN NEBEL
    OLSHAN FROME WOLOSKY LLP, 1325 Avenue of the Americas
    New York, NY, 10019
    212-451-2300

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    04/12/2026

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    schemaVersion:


    SCHEDULE 13D

    CUSIP Number(s):
    81578P106


    1 Name of reporting person

    Radoff Family Foundation
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    500,000.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    500,000.00
    11Aggregate amount beneficially owned by each reporting person

    500,000.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.9 %
    14Type of Reporting Person (See Instructions)

    CO



    SCHEDULE 13D

    CUSIP Number(s):
    81578P106


    1 Name of reporting person

    Radoff Bradley Louis
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF, PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    2,110,232.00
    8Shared Voting Power

    500,000.00
    9Sole Dispositive Power

    2,110,232.00
    10Shared Dispositive Power

    500,000.00
    11Aggregate amount beneficially owned by each reporting person

    2,610,232.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.6 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP Number(s):
    81578P106


    1 Name of reporting person

    JEC II Associates, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,167,296.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,167,296.00
    11Aggregate amount beneficially owned by each reporting person

    1,167,296.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    2.1 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP Number(s):
    81578P106


    1 Name of reporting person

    The MOS Trust
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    WYOMING
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    215,000.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    215,000.00
    11Aggregate amount beneficially owned by each reporting person

    215,000.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.4 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP Number(s):
    81578P106


    1 Name of reporting person

    MOS PTC, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    WYOMING
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    215,000.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    215,000.00
    11Aggregate amount beneficially owned by each reporting person

    215,000.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.4 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP Number(s):
    81578P106


    1 Name of reporting person

    Torok Michael
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF, PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    285,000.00
    8Shared Voting Power

    1,382,296.00
    9Sole Dispositive Power

    285,000.00
    10Shared Dispositive Power

    1,382,296.00
    11Aggregate amount beneficially owned by each reporting person

    1,667,296.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    3.0 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Class A Common Stock, par value $0.00001 per share
    (b)Name of Issuer:

    Seer, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY, CALIFORNIA , 94065.
    Item 4.Purpose of Transaction
     
    Item 4 is hereby amended to add the following: On April 13, 2026, the Reporting Persons submitted a non-binding proposal to acquire 100% of the equity of the Issuer at a purchase price of $2.25 per Share in cash, representing a 33% premium to the Issuer's most recent closing price, plus a contingent value right representing the right for stockholders to receive 80% of the net proceeds received from any license, sale or other disposition of the Issuer's business and assets, including PrognomiQ (the "Proposal"). The Proposal is only subject to limited confirmatory due diligence and is based on the availability of at least $215 million of net cash and cash equivalents at closing and is not subject to any financing conditions. The Reporting Persons requested a response regarding the Issuer's board of directors' (the "Board") willingness and availability to discuss the Proposal no later than 5:00pm ET on April 22, 2026, at which point the Proposal will expire. Also on April 13, 2026, Mr. Radoff delivered a letter to the Issuer nominating Howard H. Berman, Joshua S. Horowitz and Luis E. Rinaldini (the "Nominees") for election to the Board at the Issuer's 2026 annual meeting of stockholders (the "Annual Meeting"). Also on April 13, 2026, the Reporting Persons issued a press release (the "Press Release"), which included a copy of the Proposal delivered to the Board and announced the nomination of the Nominees for election to the Board at the Annual Meeting. The foregoing descriptions of the Proposal and the Press Release do not purport to be complete and are qualified in their entirety by reference to the full text of the Press Release, which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
    Item 5.Interest in Securities of the Issuer
    (c)
    Item 5(c) is hereby amended and restated to read as follows: There have been no transactions in the securities of the Issuer by the Reporting Persons since the filing of Amendment No. 1 to the Schedule 13D.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    Item 6 is hereby amended to add the following: On April 12, 2026, (a) Radoff (as defined in the initial Schedule 13D), (b) JEC (as defined in the initial Schedule 13D) and (c) Dr. Berman and Messrs. Horowitz and Rinaldini (collectively, the "New Parties") entered into an amended and restated group agreement (the "Amended and Restated Group Agreement") with respect to the Issuer pursuant to which, among other things, (i) that certain group agreement, dated February 20, 2026, between Radoff and JEC was superseded in its entirety, (ii) the parties agreed to the joint filing on behalf of each of them of statements on Schedule 13D with respect to the securities of the Issuer to the extent required by applicable law, (iii) the parties agreed to solicit proxies for the election of certain persons nominated for election to the Board at the Annual Meeting (including those nominated by or on behalf of Radoff or JEC), (iv) the parties agreed not to transact in securities of the Issuer without the prior written consent of Radoff and JEC for so long as the Issuer's tax benefit preservation plan, dated as of February 26, 2026 (the "NOL Pill"), remains in effect; provided, that each New Party further agreed not to enter into any transactions in the securities of the Issuer without the prior written consent of Radoff and JEC notwithstanding any potential termination of the NOL Pill and (v) Radoff and JEC agreed to jointly pay all expenses and costs (including all legal fees) incurred in connection with the group's activities on a pro rata basis based on the number of Shares beneficially owned in the aggregate by such party. The Amended and Restated Group Agreement is attached hereto as Exhibit 99.2 and is incorporated herein by reference. Each of the Nominees has granted Mr. Radoff a power of attorney (each, a "Power of Attorney") to execute certain SEC filings and other documents in connection with the solicitation of proxies at the Annual Meeting. A form of the Power of Attorney is attached hereto as Exhibit 99.3 and is incorporated herein by reference.
    Item 7.Material to be Filed as Exhibits.
     
    Item 7 is hereby amended to add the following exhibits: 99.1 - Press Release, dated April 13, 2026. 99.2 - Amended and Restated Group Agreement, dated April 12, 2026. 99.3 - Form of Power of Attorney.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Radoff Family Foundation
     
    Signature:/s/ Bradley L. Radoff
    Name/Title:Bradley L. Radoff, Director
    Date:04/13/2026
     
    Radoff Bradley Louis
     
    Signature:/s/ Bradley L. Radoff
    Name/Title:Bradley L. Radoff
    Date:04/13/2026
     
    JEC II Associates, LLC
     
    Signature:/s/ Michael Torok
    Name/Title:Michael Torok, Manager
    Date:04/13/2026
     
    The MOS Trust
     
    Signature:/s/ Michael Torok
    Name/Title:Michael Torok, Manager of MOS PTC, LLC, its Trustee
    Date:04/13/2026
     
    MOS PTC, LLC
     
    Signature:/s/ Michael Torok
    Name/Title:Michael Torok, Manager
    Date:04/13/2026
     
    Torok Michael
     
    Signature:/s/ Michael Torok
    Name/Title:Michael Torok
    Date:04/13/2026
    Get the next $SEER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SEER

    DatePrice TargetRatingAnalyst
    7/5/2023$10.00Neutral
    JP Morgan
    1/4/2023$9.00 → $6.50Neutral → Underperform
    BofA Securities
    8/11/2022$20.00 → $12.00Overweight → Neutral
    JP Morgan
    3/1/2022$23.00 → $21.00Equal-Weight
    Morgan Stanley
    2/15/2022$46.00 → $23.00Equal-Weight
    Morgan Stanley
    10/15/2021Outperform
    Cowen
    8/13/2021$55.00 → $50.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SEER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Seer Confirms Receipt of Unsolicited Proposal and Director Candidate Nominations from Radoff-JEC Group

    REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), the pioneer and trusted partner for deep, unbiased proteomic insights, today confirmed that it has received a highly contingent, non-binding and unsolicited proposal from Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group") to acquire all of the outstanding shares of Seer's Class A common stock for $2.25 per share in cash plus a contingent value right (the "Proposal"). Consistent with its fiduciary duties and in consultation with its independent financial and legal advisors, the Seer Board of Directors (the "Board") will carefully

    4/13/26 1:55:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    The Radoff-JEC Group Submits Non-Binding Proposal to Acquire Seer, Inc.

    Proposal Provides Stockholders $2.25 per Share in Cash, a 33% Premium to the Most Recent Closing Price, as Well as Potential Additional Value from the Sale of Seer's Assets via a Contingent Value Right Proposal Provides Seer Stockholders Immediate and Significant Value While Avoiding Further Value Destruction from Continued Abysmal Operating Results Nominates Three Highly Qualified Director Candidates – Howard H. Berman, Joshua S. Horowitz and Luis E. Rinaldini – for Election at Upcoming Annual Meeting Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group"), who collectively own approximately 7.6% of the outstanding shares of Seer, Inc.

    4/13/26 8:00:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer and Precision Health Research, Singapore Sign Collaboration to Provide Deep, Unbiased Proteomics on 10,000 PRECISE SG100K Samples

    REDWOOD CITY, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Proteograph® Product Suite, has been selected as the mass spectrometry-based proteomic workflow to deeply profile the plasma proteome in 10,000 participants from PRECISE-SG100K. This unbiased proteomics data set will be combined with data from Thermo Fisher Scientific's Olink® Reveal and Thermo Scientific Orbitrap Astral™ mass spectrometers, utilized on the same set of samples to enhance the proteomic insights available to researchers. PRECISE-SG100K is a landmark, multi-ancestry population-scale cohort of approx

    4/9/26 8:00:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    SEC Filings

    View All

    SEC Form DEFA14A filed by Seer Inc.

    DEFA14A - Seer, Inc. (0001726445) (Filer)

    4/13/26 6:29:58 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEFA14A filed by Seer Inc.

    DEFA14A - Seer, Inc. (0001726445) (Filer)

    4/13/26 4:56:09 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Seer, Inc. (0001726445) (Filer)

    4/13/26 4:47:50 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    JP Morgan resumed coverage on Seer with a new price target

    JP Morgan resumed coverage of Seer with a rating of Neutral and set a new price target of $10.00

    7/5/23 7:25:16 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer downgraded by BofA Securities with a new price target

    BofA Securities downgraded Seer from Neutral to Underperform and set a new price target of $6.50 from $9.00 previously

    1/4/23 9:03:59 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer downgraded by JP Morgan with a new price target

    JP Morgan downgraded Seer from Overweight to Neutral and set a new price target of $12.00 from $20.00 previously

    8/11/22 6:17:02 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CFO Horn David R. sold $15,447 worth of shares (7,743 units at $1.99), decreasing direct ownership by 2% to 501,262 units (SEC Form 4)

    4 - Seer, Inc. (0001726445) (Issuer)

    2/19/26 4:11:51 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    CEO AND CHAIR Farokhzad Omid sold $48,646 worth of shares (24,385 units at $1.99), decreasing direct ownership by 0.72% to 3,349,064 units (SEC Form 4)

    4 - Seer, Inc. (0001726445) (Issuer)

    2/19/26 4:06:45 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PRESIDENT & CFO Horn David R. was granted 79,000 shares, increasing direct ownership by 18% to 509,005 units (SEC Form 4)

    4 - Seer, Inc. (0001726445) (Issuer)

    2/5/26 6:54:29 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Financials

    Live finance-specific insights

    View All

    Seer Adopts Limited Duration Tax Benefit Preservation Plan to Protect its Valuable Tax Assets

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors unanimously adopted a tax benefit preservation plan ("NOL Plan") designed to help preserve and protect Seer's valuable income tax net operating loss carryforwards and other tax assets ("NOLs"). As of December 31, 2025, Seer had approximately $262 million of NOLs. These NOLs, most of which are not currently subject to any expiration date, represent a valuable asset of Seer and are available to reduce Seer's future federal income tax expense. The NOL Plan is similar to those adopted by numerous o

    2/26/26 4:06:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Outlook

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Generated revenue of $4.2 million for the fourth quarter of 2025 and $16.6 million for the full year 2025Expanded installed base to 82 instruments, representing 67% year-over-year growth, with 33 total instruments installed during the full year 2025Seminal customer studies published in Nature and Nature Genetics highlighting the power of the Proteograph to enable clinically relevant biomarker discovery and deep biologic insigh

    2/26/26 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the fourth quarter and full year 2025 on Thursday, February 26, 2026. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer is a life sciences company developing transformative products that open a new gateway to th

    2/5/26 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Leadership Updates

    Live Leadership Updates

    View All

    Seer Appoints Isaac Ro to its Board of Directors

    REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors. "We are excited to welcome Isaac to our board," said Omid Farokhzad, Chair and CEO of Seer. "Isaac brings a rare combination of financial leadership and deep sector experience across life science tools, diagnostics, and the broader healthcare ecosystem. His proven track record of guiding companies through transformative growth will be invaluable as we continue to execute on key milestones and accelerate the impact of our platform." "I'm looking forward to work

    9/2/25 7:00:00 AM ET
    $SEER
    $WGS
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Retail: Computer Software & Peripheral Equipment
    Technology

    Seer Appoints Nicolas Roelofs to its Board of Directors

    REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas Roelofs to serve on its Board of Directors. "Nick is a fantastic addition to our board, bringing over 35 years of broad operational and advisory experience with leading healthcare, life science tools, and diagnostics companies," said Omid Farokhzad, Chair and CEO of Seer. "His extensive experience and insights will be valuable as we advance our mission of opening up a new gateway to the proteome." "I'm excited to work with the Seer team and leverage my experience in the life

    8/14/24 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Announces Appointment of Scott D. Thomas as Chief Commercial Officer

    REDWOOD CITY, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, announced today the appointment of Scott D. Thomas as Chief Commercial Officer effective March 21, 2022. Mr. Thomas joins Seer from Singular Genomics, where he served as Senior Vice President, Sales and Marketing. Prior to Singular, he spent over two decades with increasing commercial responsibilities within the life sciences industry, including 11 years at Illumina. "I'm thrilled to welcome Scott, whose leadership and breadth of expertise in the commercialization of life sciences tools complements the balance of our talented

    3/16/22 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Seer Inc.

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    8/2/24 6:33:25 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Seer Inc.

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    7/8/24 4:32:39 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Seer Inc. (Amendment)

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    4/10/24 10:06:09 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials